Connor, Clark & Lunn Investment Management Ltd. Eiger Bio Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$22 Billion
Q2 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$1.02 - $7.48 $11,002 - $80,686	-10,787 Reduced 22.16%	37,881 $44,000
Q3 2022 Nov 10, 2022	BUY	$6.04 - $9.66 $207,135 - $331,280	34,294 Added 238.58%	48,668 $366,000
Q2 2022 Aug 05, 2022	SELL	$4.99 - $8.96 $43,772 - $78,597	-8,772 Reduced 37.9%	14,374 $91,000
Q1 2022 May 12, 2022	BUY	$3.84 - $9.74 $88,880 - $225,442	23,146 New	23,146 $192,000
Q4 2020 Feb 16, 2021	SELL	$7.98 - $12.29 $99,821 - $153,735	-12,509 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$7.96 - $12.42 $519,684 - $810,864	-65,287 Reduced 83.92%	12,509 $102,000
Q2 2020 Aug 13, 2020	SELL	$5.4 - $13.37 $30,531 - $75,593	-5,654 Reduced 6.78%	77,796 $747,000
Q1 2020 May 13, 2020	BUY	$4.91 - $14.7 $339,158 - $1.02 Million	69,075 Added 480.52%	83,450 $567,000
Q4 2019 Feb 12, 2020	BUY	$9.77 - $15.66 $140,443 - $225,112	14,375 New	14,375 $214,000

Others Institutions Holding EIGR

# of Institutions

Shares Held

748K

Call Options Held

Put Options Held

View Full List

About Eiger BioPharmaceuticals, Inc.

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

More about EIGR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account